Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigeo Fuji

Showing results (71-80 of 191) with videos related to

Pageof 20
Sort By:
International Journal of Hematology|November 25, 2024
Impact of stem cell source on secondary steroid for chronic GVHD after allogeneic hematopoietic cell transplantationKazuhiro Sanda, Shigeo Fuji, Yuma Tada, et al.
HLA|March 15, 2020
Wide availability of HLA-matched or a few loci-mismatched donors in the graft-vs-host direction among nonsibling first-degree relativesMizuki Watanabe, Junya Kanda, Hiroto Kojima, et al.
Internal Medicine (Tokyo, Japan)|July 19, 2017
Therapy-related Acute Myeloid Leukemia after the Long-term Administration of Low-dose Etoposide for Chronic-type Adult T-cell Leukemia-lymphoma: A Case Report and Literature ReviewNaoki Shimada, Nobuhiro Ohno, Ryuji Tanosaki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 21, 2019
Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell TransplantationSayako Yuda, Shigeo Fuji, Akio Onishi, et al.
Journal of Medical Economics|September 1, 2023
Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in JapanTakashi Mizuoka, Hiroyuki Sakamaki, Shigeo Fuji, et al.
Journal of Medical Economics|February 18, 2026
Health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general populationShigeo Fuji, Hiroshi Ando, Kana Takaura, et al.
Annals of Hematology|March 26, 2025
Improving outcome prediction in indolent ATL by subdividing intermediate risk into low- and high-intermediate groupsShigeo Fuji, Masahito Tokunaga, Atae Utsunomiya, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 20, 2016
Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell TransplantationTakashi Tanaka, Yoshihiro Inamoto, Takuya Yamashita, et al.
Blood Cell Therapy|October 27, 2023
Kinetics of neutrophil engraftment in allogeneic stem cell transplantationAkihisa Kawajiri, Shigeo Fuji, Yoshihiro Inamoto, et al.
Blood Cell Therapy|December 26, 2023
Gilteritinib in peritransplant period for relapsed or refractory FLT3-mutated acute myeloid leukemia: A case report of three patientsFuka Mima, Shigeo Fuji, Kumi Shibata, et al.
Pageof 20

Showing results (71-80 of 191) with videos related to

Sort By:
Pageof 20
International Journal of Hematology|November 25, 2024
Impact of stem cell source on secondary steroid for chronic GVHD after allogeneic hematopoietic cell transplantationKazuhiro Sanda, Shigeo Fuji, Yuma Tada, et al.
HLA|March 15, 2020
Wide availability of HLA-matched or a few loci-mismatched donors in the graft-vs-host direction among nonsibling first-degree relativesMizuki Watanabe, Junya Kanda, Hiroto Kojima, et al.
Internal Medicine (Tokyo, Japan)|July 19, 2017
Therapy-related Acute Myeloid Leukemia after the Long-term Administration of Low-dose Etoposide for Chronic-type Adult T-cell Leukemia-lymphoma: A Case Report and Literature ReviewNaoki Shimada, Nobuhiro Ohno, Ryuji Tanosaki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 21, 2019
Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell TransplantationSayako Yuda, Shigeo Fuji, Akio Onishi, et al.
Journal of Medical Economics|September 1, 2023
Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in JapanTakashi Mizuoka, Hiroyuki Sakamaki, Shigeo Fuji, et al.
Journal of Medical Economics|February 18, 2026
Health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general populationShigeo Fuji, Hiroshi Ando, Kana Takaura, et al.
Annals of Hematology|March 26, 2025
Improving outcome prediction in indolent ATL by subdividing intermediate risk into low- and high-intermediate groupsShigeo Fuji, Masahito Tokunaga, Atae Utsunomiya, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 20, 2016
Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell TransplantationTakashi Tanaka, Yoshihiro Inamoto, Takuya Yamashita, et al.
Blood Cell Therapy|October 27, 2023
Kinetics of neutrophil engraftment in allogeneic stem cell transplantationAkihisa Kawajiri, Shigeo Fuji, Yoshihiro Inamoto, et al.
Blood Cell Therapy|December 26, 2023
Gilteritinib in peritransplant period for relapsed or refractory FLT3-mutated acute myeloid leukemia: A case report of three patientsFuka Mima, Shigeo Fuji, Kumi Shibata, et al.
Pageof 20